BR112018006121A2 - fármacos antiestrogênicos de tetra-hidro-1h-pirido[3,4-b]indol - Google Patents

fármacos antiestrogênicos de tetra-hidro-1h-pirido[3,4-b]indol

Info

Publication number
BR112018006121A2
BR112018006121A2 BR112018006121A BR112018006121A BR112018006121A2 BR 112018006121 A2 BR112018006121 A2 BR 112018006121A2 BR 112018006121 A BR112018006121 A BR 112018006121A BR 112018006121 A BR112018006121 A BR 112018006121A BR 112018006121 A2 BR112018006121 A2 BR 112018006121A2
Authority
BR
Brazil
Prior art keywords
pyrido
tetrahydro
estrogen drugs
indole
indole anti
Prior art date
Application number
BR112018006121A
Other languages
English (en)
Other versions
BR112018006121B1 (pt
Inventor
L Harmon Cyrus
C Myles David
J Kushner Peter
Original Assignee
Olema Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc filed Critical Olema Pharmaceuticals Inc
Priority to BR122023020677-0A priority Critical patent/BR122023020677A2/pt
Publication of BR112018006121A2 publication Critical patent/BR112018006121A2/pt
Publication of BR112018006121B1 publication Critical patent/BR112018006121B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos de tetra-hidro-1h-pirido[3,4-b]indol ou um sal, solvato, hidrato, pró-fármaco, estereoisômero, tautômero, rotâmero, n-óxido e/ou derivado substituído farmaceuticamente aceitável ou, opcionalmente em uma composição farmacêutica, para a modulação de transtornos mediados por estrogênio, ou outros transtornos como mais completamente descritos aqui.
BR112018006121-2A 2015-10-01 2016-09-29 COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS BR112018006121B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023020677-0A BR122023020677A2 (pt) 2015-10-01 2016-09-29 Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562235900P 2015-10-01 2015-10-01
US62/235,900 2015-10-01
PCT/US2016/054549 WO2017059139A1 (en) 2015-10-01 2016-09-29 TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS

Publications (2)

Publication Number Publication Date
BR112018006121A2 true BR112018006121A2 (pt) 2018-10-23
BR112018006121B1 BR112018006121B1 (pt) 2024-01-23

Family

ID=58427985

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112018006121-2A BR112018006121B1 (pt) 2015-10-01 2016-09-29 COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS
BR122023020677-0A BR122023020677A2 (pt) 2015-10-01 2016-09-29 Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122023020677-0A BR122023020677A2 (pt) 2015-10-01 2016-09-29 Compostos de tetra-hidro-1h-pirido[3,4-b]indol, composições compreendendo os referidos compostos e usos dos mesmos

Country Status (24)

Country Link
US (4) US10292971B2 (pt)
EP (2) EP3355884B1 (pt)
JP (3) JP6776348B2 (pt)
KR (1) KR20180071274A (pt)
CN (2) CN113248494A (pt)
AU (3) AU2016331065B2 (pt)
BR (2) BR112018006121B1 (pt)
CA (1) CA3000410A1 (pt)
CL (1) CL2018000827A1 (pt)
CY (1) CY1124669T1 (pt)
DK (1) DK3355884T3 (pt)
ES (1) ES2881398T3 (pt)
HR (1) HRP20211124T1 (pt)
HU (1) HUE055321T2 (pt)
IL (3) IL310489A (pt)
LT (1) LT3355884T (pt)
MX (2) MX2018003929A (pt)
PL (1) PL3355884T3 (pt)
PT (1) PT3355884T (pt)
RS (1) RS62133B1 (pt)
RU (2) RU2745742C1 (pt)
SI (1) SI3355884T1 (pt)
UA (1) UA122346C2 (pt)
WO (1) WO2017059139A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6679147B2 (ja) 2014-12-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment
WO2017100715A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulator compounds
WO2017136688A1 (en) 2016-02-05 2017-08-10 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2018019793A1 (en) * 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
MX2019004685A (es) 2016-10-24 2019-08-21 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
BR112019013814A2 (pt) 2017-01-06 2020-01-21 G1 Therapeutics Inc método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
TWI794205B (zh) 2017-01-30 2023-03-01 瑞典商阿斯特捷利康公司 化合物
JP2020507566A (ja) 2017-02-10 2020-03-12 ジー１ セラピューティクス， インコーポレイテッド ベンゾチオフェンエストロゲン受容体モジュレーター
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
MX2020011531A (es) 2018-06-21 2021-03-25 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
WO2020132785A1 (en) * 2018-12-24 2020-07-02 Inventisbio Shanghai Ltd. Novel salts of selective estrogen receptor degraders
WO2020232119A1 (en) 2019-05-14 2020-11-19 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN114302722A (zh) * 2019-07-07 2022-04-08 奥列马制药公司 雌激素受体拮抗剂方案
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
AU2021230588A1 (en) * 2020-03-06 2022-08-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
EP4267578A1 (en) 2020-12-23 2023-11-01 Recurium IP Holdings, LLC Estrogen receptor modulators
CN116744920A (zh) * 2021-02-08 2023-09-12 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
IL308104A (en) 2021-05-03 2023-12-01 Nuvation Bio Inc Nuclear hormone receptor-targeted compounds against cancer
IL309986A (en) * 2021-07-08 2024-03-01 Olema Pharmaceuticals Inc Methods for treating diseases related to estrogen receptors
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer
WO2024039861A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039860A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
WO2024039858A1 (en) 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2024076633A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024076626A1 (en) * 2022-10-05 2024-04-11 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
TW366342B (en) 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
ATE247114T1 (de) 1994-09-12 2003-08-15 Lilly Co Eli Serotonergische modulatoren
US5880137A (en) 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5998402A (en) 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
TW397821B (en) 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
ID24568A (id) 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
CO5271696A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271697A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20020013327A1 (en) 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
EP1359940A2 (en) 2000-07-06 2003-11-12 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
AR030064A1 (es) 2000-07-06 2003-08-13 Wyeth Corp Metodos para inhibir los efectos uterotroficos de los agentes estrogenicos
MXPA03000170A (es) 2000-07-06 2003-05-27 Wyeth Corp Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos.
WO2002003989A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating sphincter incontinence
MXPA02012897A (es) 2000-07-06 2003-10-24 Wyeth Corp Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos.
US20020016318A1 (en) 2000-07-06 2002-02-07 American Home Products Corporation Methods of treating breast disorders
WO2002003991A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
EP1177787A3 (en) 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
US6511986B2 (en) 2000-08-11 2003-01-28 Wyeth Method of treating estrogen receptor positive carcinoma
EP1192945A3 (en) 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145838A (en) 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
CZ2004220A3 (cs) 2001-08-11 2004-06-16 Bristol-Myers Squibb Pharma Company Název neuveden
US7863310B2 (en) 2004-02-03 2011-01-04 Eli Lilly And Company Kinase inhibitors
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
DK1737461T3 (da) * 2004-03-15 2013-03-18 Ptc Therapeutics Inc Carbolin-derivater til inhibering af angiogenese
EP1846397A1 (en) 2005-01-21 2007-10-24 Janssen Pharmaceutica N.V. Novel heterocyclic benzoy[c]chromene derivatives useful as modulators of the estrogen receptors
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел
CA2763485C (en) 2009-05-27 2018-05-15 Neil Almstead Methods for treating cancer and non-neoplastic conditions
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
ES2586908T3 (es) * 2010-12-24 2016-10-19 Merck Sharp & Dohme B.V. Derivados de azetidina N-sustituidos
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
PL3004090T3 (pl) * 2013-05-28 2018-02-28 Astrazeneca Ab Związki chemiczne
JP6576916B2 (ja) * 2013-06-19 2019-09-18 セラゴン ファーマシューティカルズ， インク． エストロゲン受容体モジュレーター及びその使用
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
EP3010502B1 (en) 2013-06-19 2018-11-21 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2016062926A1 (en) * 2014-10-23 2016-04-28 Oy Mtg-Meltron Ltd Lighting apparatus for hazardous areas
KR101989608B1 (ko) * 2014-10-31 2019-06-14 카스턴 매뉴팩츄어링 코오포레이숀 골프 클럽 헤드의 그루브 및 골프 클럽 헤드의 그루브의 제조 방법
JP6679147B2 (ja) * 2014-12-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
IL310489A (en) 2015-10-01 2024-03-01 Olema Pharmaceuticals Inc Tetrahydro-1H-pyrido[3,4-b]indole anti-estrogenic drugs and preparations containing them for use in cancer treatment
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
MX2019004685A (es) 2016-10-24 2019-08-21 Astrazeneca Ab Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina utiles en el tratamiento del cancer.
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
PL3820874T3 (pl) 2018-07-12 2023-02-06 Eli Lilly And Company Selektywne środki degradujące receptor estrogenowy

Also Published As

Publication number Publication date
CN108366996B (zh) 2021-04-09
US10624878B2 (en) 2020-04-21
UA122346C2 (uk) 2020-10-26
IL258363B (en) 2021-10-31
JP6776348B2 (ja) 2020-10-28
RS62133B1 (sr) 2021-08-31
JP2023087106A (ja) 2023-06-22
RU2021107754A (ru) 2021-04-01
CL2018000827A1 (es) 2018-09-28
DK3355884T3 (da) 2021-08-02
PL3355884T3 (pl) 2021-11-29
MX2021005214A (es) 2021-06-18
CA3000410A1 (en) 2017-04-06
WO2017059139A1 (en) 2017-04-06
BR122023020677A2 (pt) 2023-12-12
IL310489A (en) 2024-03-01
US20220370421A1 (en) 2022-11-24
US20210059991A1 (en) 2021-03-04
US20190247372A1 (en) 2019-08-15
HRP20211124T1 (hr) 2021-10-15
LT3355884T (lt) 2021-07-26
US11229630B2 (en) 2022-01-25
AU2023202620A1 (en) 2023-05-18
US20240131013A1 (en) 2024-04-25
US10292971B2 (en) 2019-05-21
EP3355884B1 (en) 2021-04-28
JP2018530549A (ja) 2018-10-18
BR112018006121B1 (pt) 2024-01-23
MX2018003929A (es) 2018-11-22
SI3355884T1 (sl) 2021-11-30
KR20180071274A (ko) 2018-06-27
AU2021206861B2 (en) 2023-02-02
ES2881398T3 (es) 2021-11-29
AU2016331065A1 (en) 2018-04-26
AU2016331065B2 (en) 2021-04-29
HUE055321T2 (hu) 2021-11-29
EP3355884A1 (en) 2018-08-08
JP2021001231A (ja) 2021-01-07
EP3355884A4 (en) 2019-06-05
CN108366996A (zh) 2018-08-03
RU2745742C1 (ru) 2021-03-31
PT3355884T (pt) 2021-07-26
JP7277424B2 (ja) 2023-05-19
CN113248494A (zh) 2021-08-13
CY1124669T1 (el) 2022-07-22
IL286518A (en) 2021-10-31
EP3912680A1 (en) 2021-11-24
AU2021206861A1 (en) 2021-08-12
IL286518B2 (en) 2024-06-01
IL286518B1 (en) 2024-02-01
IL258363A (en) 2018-05-31
US20180289679A1 (en) 2018-10-11
US11672785B2 (en) 2023-06-13

Similar Documents

Publication Publication Date Title
BR112018006121A2 (pt) fármacos antiestrogênicos de tetra-hidro-1h-pirido[3,4-b]indol
PH12017501140A1 (en) TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
AU2015336400A8 (en) Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
BR112016026552A8 (pt) derivados de carboxamida, seus usos, composição farmacêutica, e combinação
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
MX2017001603A (es) Derivados de piperazina como moduladores de los receptores x del higado.
MX2013008269A (es) Composicion farmaceutica que comprende derivados de piridona.
BR112018009413A2 (pt) formulação oral sólida e método para preparar a formulação oral sólida
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
MX2017001869A (es) Formas cristalinas de un modulador de receptor de estrogeno.
WO2014160143A3 (en) Isatin compounds, compositions and methods for treatment of degenerative diseases and disorders
PH12017501736A1 (en) Indole derivatives
BR112018003335A2 (pt) composições farmacêuticas compreendendo 3-(5-amino-2-metil-4-oxo-4h-quinazolina-3-il)-piperidina-2,6-diona
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
CA2905957C (en) Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023020677-0 PROTOCOLO 870230088623 EM 05/10/2023 17:35.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2016, OBSERVADAS AS CONDICOES LEGAIS